

CONTENTS

Preface	xxii
Contributors	xxv
Biomarkers: An Evolutionary Perspective	1
<i>Michael A. Ferguson and Vishal S. Vaidya</i>	
References	4
SECTION I: TOOLS FOR BIOMARKER DISCOVERY	5
2 Genomics	7
<i>Weida Tong and Donna L. Mendrick</i>	
Introduction	7
Evaluation of the Technology	8
Clinical Applications	10
Bioinformatics Challenges	12
Applications to Drug Toxicology, Medicine, and Environmental Health	14
Improve Understanding of Basic Cellular Architecture and Function	15
Mechanism of Toxicity and Disease	16
Algorithmic Models to Predict Toxicity or Disease	17
Strengths, Weaknesses, and the Road Forward	18
Conclusion	20
Summary Points	20
Disclaimer	20
References	20
3 Proteomics for Biomarker Discovery	25
<i>Timothy D. Veenstra</i>	
Introduction	25

Tissue or Biofluid	26
Technology	28
Protein Identification Using Mass Spectrometry	29
Sample Preparation	30
Protein Quantitation	33
Examples of Biomarker Discovery and Evaluation	35
Challenges in Proteomic Biomarker Discovery	38
The Road Forward: Targeted Verification and Validation	39
Conclusion	43
Summary Points	44
Acknowledgments	44
References	44
4 Metabolic Profiling for Biomarker Discovery	47
<i>Hector C. Keun</i>	
Introduction: What is Metabolic Profiling?	47
Analytical Strategies for Metabolic Profiling	50
Data Pre-Processing, Analysis, and Pattern Recognition	54
Preclinical Toxicology: Models for Pathological Biomarker Discovery	56
Disease Biomarker Discovery Using Metabolic Profiling	58
Inborn Errors of Metabolism	58
Neuroscience	59
Cancer	59
Infectious Disease	61
Metabolic Syndrome: Insulin Resistance, Cardiovascular Disease, and Hypertension	61
Environmental Health and Metabolic Profiling	62
Conclusion: Strengths, Weaknesses, and the Way Forward for Metabolic Profiling in Biomarker Discovery	63
Summary Points	64
References	64
5 The Bittersweet Promise of Glycobiology	75
<i>Padmaparna Chaudhuri, Rania Harfouche, and Shiladitya Sengupta</i>	
Introduction	75
Glycosylation in Pathological States	75
Congenital Disorders of Glycosylation (CDG)	75
Glycomics of Immune Disorders	76
Glycomics in Cancer	77
Other Acquired Diseases	79
Glycans in Therapeutics and as Therapeutic Targets	79
Tools to Analyze the Glycome	80

Analytical	80
Chemical	81
Microarray	82
Molecular	83
Strengths, Weaknesses, and the Road Forward	84
Conclusion	84
Summary Points	84
References	85

SECTION II: BIOMARKERS OF INJURY/DISEASE 89

6 Biomarkers of Alzheimer's and Parkinson's Disease 91

Walter Maetzler and Daniela Berg

Definition and Prevalence of Alzheimer's and Parkinson's Disease	91
Alzheimer's Disease	91
Parkinson's Disease	92
Pathophysiology and Mechanisms	92
Alzheimer's Disease	92
Genetic Aspects	93
Pathology	93
Pathophysiological Mechanisms	94
Parkinson's Disease	95
Genetic Aspects	95
Pathology	96
Pathophysiological Mechanisms	96
Concluding Remarks to Pathological and Pathophysiological Aspects	97
Current Means for Diagnosis/Prognosis of the Diseases and Their Limitations	98
Alzheimer's Disease	98
Clinical Markers	98
Genetic Markers	98
In Vivo Markers from Pathology	98
Pathophysiological Mechanisms	100
Further Diagnostic Assessments	100
Parkinson's Disease	100
Clinical Markers	101
Genetic Markers	101
In Vivo Markers from Pathology	101
Pathophysiological Mechanisms	102
Further Diagnostic Assessments	102
Novel Biomarkers	102
Alzheimer's Disease	102

Clinical Markers	102
Genetic Markers	102
In Vivo Markers from Pathology	103
Pathophysiological Mechanisms	104
Further Diagnostic Assessments	105
Combination of Markers	105
Parkinson's Disease	106
Clinical Markers	106
Genetic Markers	106
In Vivo Markers from Pathology	106
Pathophysiological Mechanisms	107
Further Diagnostic Assessments	107
Combination of Markers	108
Methods to Quantify Biomarkers	108
Conclusion	109
Summary Points	109
References	110
7 Biomarkers of Cardiac Injury	119
<i>Anthony S. McLean and Stephen J. Huang</i>	
Introduction	119
Definition and Prevalence	119
Pathophysiology and Mechanisms	123
Diagnosis	125
Biomarkers of Cardiac Injury	126
Inflammatory Markers of Cardiac Disease	127
C-Reactive Protein (CRP)	127
Interleukins (IL)	129
Tumor Necrosis Factor (TNF) and Fas	129
CD40 Ligand	130
Matrix Metalloproteinases (MMPs)	130
Myeloperoxidase (MPO)	131
Markers for Myocardial Cell Injury	131
Creatine Kinase-Myocardial Band (CK-MB)	131
Troponins (cTn)	132
Heart-Type Fatty Acid Binding Protein (H-FABP)	134
Markers for Cardiac Stress	134
B-Type Natriuretic Peptide (BNP) and N-Terminal ProBNP (NT-ProBNP)	134
Adrenomedullin (ADM)	137
ST2	138
Multimarker Approach?	138
Conclusion	139

Summary Points	139
References	140
8 Lung Injury Biomarkers	157
<i>Urmila P. Kodavanti</i>	
Introduction	157
Causes of Lung Injury	158
Morphological and Cellular Targets of Lung Injury	159
Airway and Mucosa	159
Alveolar Macrophage	161
The Surfactant Covering Alveolar Epithelial Cells	161
Alveolar Epithelium, Interstitium, and Capillary Endothelium	162
Pathobiologic Processes Involved in Lung Injuries and Diseases	162
Airway Epithelial Damage, Mucus Hypersecretion, and Goblet Cell Hyperplasia	162
Airway Inflammation in Asthma	164
Airway Inflammation in Bronchitis and Chronic Obstructive Pulmonary Disease	164
Airway Fibrosis, Bronchoconstriction, and Hyperresponsiveness	165
Alveolar Epithelial, Capillary Endothelial, and Terminal Bronchiolar Injuries	166
Pulmonary Edema	166
Neutrophilic Inflammation, Alveolar Apoptosis, and Emphysema	167
Pulmonary Fibrosis and Granuloma	167
Alveolar Phospholipidosis	169
Pulmonary Surfactant and Surfactant Protein Abnormalities	169
Sampling Techniques for Biomarker Analysis	170
Induced Sputum	170
Bronchoscopy and Lung Biopsy	171
Bronchoalveolar Lavage for Analysis of Biomarkers of Lung Injury	171
Biomarker Assessments and Their Involvement in Lung Injury and Disease	172
Lung Injury Biomarkers in Bronchoalveolar Lavage Fluid (BALF) and Sputum	174
Total Protein and Albumin	174
Lactate Dehydrogenase Activity	175
γ -Glutamyl Transferase Activity	175
N-acetyl Glucosaminidase Activity	175
Cells in Bronchoalveolar Lavage Fluid as Biomarkers of Lung Inflammation	176
Cytokines and Chemokines in Sputum and Bronchoalveolar Lavage Fluid	177
Biomarkers of Oxidative Stress in Bronchoalveolar Lavage	

Fluid, Sputum, Lung, and Plasma	177
Ascorbate	178
Glutathione	179
Extracellular Superoxide Dismutase	179
Ferritin, Lactoferrin, Transferrin, and Iron-Binding Capacities	180
4-Hydroxynonenal	180
F(2)-Isoprostanes	180
Exhaled Nitric Oxide	181
Heme Oxygenase-1	181
Asymmetric and Symmetric Dimethyl Arginine	182
Surfactant Proteins in Bronchoalveolar Lavage Fluid and Plasma	182
Matrix Metalloproteases as Biomarkers of Lung Injury	183
Collagen and Elastin Fragments as Biomarkers of Lung Injury	184
Circulating Lung-Cell-Specific Proteins as Biomarkers	184
Blood Coagulation and Thrombosis Markers in Lung Injuries	185
Novel Approaches for Biomarker Identification	185
Acknowledgments	187
Disclaimer	187
References	187
9 Translational Biomarkers of Acute Drug-Induced Liver Injury: The Current State, Gaps, and Future Opportunities	203
<i>Josef S. Ozer, William J. Reagan, Shelli Schomaker, Joe Palandra, Mike Baratta, and Shashi Ramaiah</i>	
Intrinsic and Idiosyncratic Drug-Induced Liver Injury:	
Terminologies and Background	203
Histological Manifestations of Liver Injury	204
Hepatic Steatosis/Fatty Liver and Steatohepatitis	204
Cholestatic Liver Injury	204
Common Mechanisms of Acute Liver Injury	205
Mechanistic Manifestations of DILI	205
Processes of Hepatocyte Cell Death	205
The Role of Immune Responses in Liver Injury	206
Metabolic Idiosyncrasy in Liver Injury	206
Underlying Inflammation Mechanisms with Liver Injury	207
Mitochondrial Oxidant Stress and Dysfunction	207
Inhibition of Tissue Repair Response	208
Disruption of Calcium Homeostasis and Cell Membrane Damage in Liver	208
Disruption of Cytoskeleton in Liver Injury	208
Traditional Preclinical and Clinical Biomarkers of Drug-Induced Liver Injury	209
Gaps in Traditional Hepatic Biomarkers	209
Considerations to Predict Acute Liver Injury: Anatomy and Time-Course	210

New and Emerging Serum Enzyme Biomarkers of Liver Injury	212
Discovery and Application of Purine Nucleoside Phosphorylase (PNP), Paroxonase (PON-1), and Malate Dehydrogenase (MDH) as Hepatic Biomarkers	212
PON1 Is a Functional Marker of Chronic Liver Injury	213
Malate Dehydrogenase (MDH) Activity Is a Candidate Biomarker of DILI-1	214
Biomarker Qualification by the Predictive Safety Testing Consortium (PSTC)	214
ALT Isozymes: ALT1 and ALT2	214
Historical Background of ALT Biology	214
Gene Expression of ALT Isoforms	216
The Localization of ALT Protein in Tissues	216
ALT Protein Levels in Serum	217
Current Knowledge on Biology of ALT	217
Does Metabolic Syndrome Illicit a Conflicting ALT Signal for DILI?	218
Anorexia Shows Metabolic Indicators of Liver Injury Including Subtle ALT Elevations	218
Biomarkers of Biliary Injury	219
Authors' Opinion on Future Biomarkers of Liver Injury, Novel Approaches, and Platforms	219
Reactive Oxygen Species (ROS) as Potential Markers for Liver Injury Mechanisms	219
Inflammation Markers as Potential Indicators of Liver Injury	220
Novel Hepatocellular Leakage Enzymes as Early Biomarkers of Symptomatic Change	221
Hepatic Regeneration Markers to Supplement Injury Biomarkers	222
Unification of Diagnostic Metrics of Liver Fibrosis	222
Analytical Biomarker Platforms to Assay Serum Biomarkers of Liver Injury	223
Mass Spectrometry Technologies Can Fill Gaps to Detect Biomarkers When Antibody Approaches are Limited	223
An Overview of Mass Spectrometry Technologies	224
Mass Spectrometry Technologies to Potentially Detect Biomarkers and Rare Protein Antigens of Injury	224
Improved Tagging Techniques for Mass Spectrometry Detection of Proteins	224
High-Throughput Chromatography Enhances the Downstream Detection of Rare Serum Proteins by Mass Spectrometry	225
Mass Spectrometry Approaches to Distinguish Novel Biomarkers of Renal and Liver Injury	226
Mass Spectrometry Approaches to Detect Novel Serum Biomarkers of Liver Injury	226
Conclusion	226

Acknowledgments	227
Summary Points	227
References	227
10 Biomarkers of Acute Kidney Injury	237
<i>Frank Dieterle and Frank D. Sistare</i>	
Introduction	237
Definition and Prevalence of Acute Kidney Injury	237
Pathophysiology and Mechanisms	238
Current Standards for Diagnosing Acute Kidney Injury	242
Novel Kidney Safety Biomarkers	244
Kidney Function Biomarkers	245
Serum Cystatin C	245
Functional Biomarkers	246
Urinary Total Protein	246
Urinary Albumin	247
Urinary β 2-Microglobulin	248
Urinary Cystatin C	249
Leakage Markers	250
Urinary GST- α and GST- μ/π	250
Urinary NAG	251
Expression Markers	251
Urinary Kim-1	251
Urinary Clusterin	253
Urinary NGAL	253
Urinary Osteoactivin	255
Urinary Osteopontin	255
Urinary L-FABP	256
Urinary Trefoil Factor 3	257
Immune Markers	257
Urinary IL-18	257
Newest Technologies and Achievements Around Kidney Safety Biomarkers	258
Assays and Technologies	258
Consortia Achieving the First Regulatory Qualification of Kidney Safety Biomarkers	260
Conclusion	261
Summary Points	263
References	263
11 In Search of Biomarkers for Drug-Induced Vascular Injury	281
<i>James R. Turk</i>	
History and Background of DIVI	281
Overview	281

Types of Compounds Implicated	282
Descriptive Pathology of Drug-Induced Vascular Injury	283
Vascular Anatomy	283
Rat	284
Dog	284
Primate	285
Spontaneous Lesions in Preclinical Species	285
Comparison with Human Vasculitides	285
Progress in Biomarker and Model Development for Drug-Induced Vascular Injury	286
Alpha-1-Acid Glycoprotein	286
Calprotectin (S100A9/A8)	286
Caveolin-1	286
Circulating Endothelial Cells/Particles	288
Complement Component 3	288
Connective Tissue Growth Factor (CTGF)	288
C-Reactive Protein (CRP)	289
Endothelin-1	289
Fibrinogen	289
GRO/CINC-1	289
Haptoglobin	289
Metallothionein-1 (MT-1)	290
Monocyte Chemoattractant Protein-1 (MCP-1)	290
Neutrophil Gelatinase-Associated Lipocalin (NGAL)	290
Osteopontin (OPN)	290
Smooth Muscle Actin	291
Thrombospondin-1 (TSP-1)	291
Tissue Inhibitor of Metalloproteinases-1 (TIMP-1)	291
Tissue Plasminogen Activator (tPA)	291
Vascular Cell Adhesion Molecule 1 (VCAM-1)	291
Vascular Endothelial Growth Factor (VEGF)	292
Von Willebrand Factor	292
Conclusion	292
References	292
12 Biomarkers of Immunotoxicity	307
<i>Rodney R. Dietert</i>	
Introduction	307
History of the Use of Biomarkers in Immunotoxicity Assessment	308
Establishing the Testing Paradigm	308
A "Challenging" Issue for Immune Biomarkers	308
Targets of Immunotoxicity	309

Diseases of Primary Concern	310
Increased Susceptibility to Infections and Tumors	310
Chronic Diseases and Conditions Based on Immune Dysfunction	310
Developmental Immunotoxicity: Increased Vulnerability in Early Life	313
Differential Exposure-Outcomes Between Genders	314
A Disease-Based Approach to Immune Biomarker Selection	314
Toxicogenomic and In Vitro Approaches	315
Conclusion	316
Summary Points	316
Acknowledgments	317
References	317
13 Biomarkers in Obstetric Medicine	323
<i>Manish Maski, Sarosh Rana, and S. Ananth Karumanchi</i>	
Aneuploidies-Trisomies 21, 18, and 13	323
Alpha Fetoprotein	323
Human Chorionic Gonadotropin	324
Pregnancy-Associated Plasma Protein-A	324
Unconjugated Estriol	325
Inhibin A	325
Detection of Trisomy 21	325
Detection of Trisomy 18	327
Detection of Trisomy 13	327
Amniocentesis and Chorionic Villi Sampling	334
Other Novel Markers for Aneuploidy Screening	334
Preeclampsia and Fetal Growth Restriction	335
Vascular Endothelial Growth Factor	335
Placental Growth Factor	336
VEGF Receptors	337
VEGFR1/Flt1 (Fms-Like Tyrosine Kinase 1)	337
Endoglin	338
Role of Angiogenic Factors in the Pathogenesis of Preeclampsia	338
The Ability of Angiogenic Proteins to Predict Preeclampsia	339
Other Potential Biomarkers for the Prediction of Preeclampsia	340
Angiogenic Factors and Intrauterine Growth Restriction	341
Preterm Labor and Other Pregnancy Complications	342
Preterm Labor	342
Abruptio	343
Gestational Diabetes	343
Summary Points	344
References	344

14 Biomarkers in Cancer	355
<i>Roopali Roy, Christine M. Coticchia, Jiang Yang, and Marsha A. Moses</i>	
Introduction	355
Cancer Biomarker Discovery Strategies	356
Cancer Biomarkers	357
Breast Cancer	357
Prostate Cancer	362
Ovarian Cancer	364
Pancreatic Cancer	367
Conclusion	369
Summary Points	370
Acknowledgments	370
References	370
15 Biomarkers of HIV	381
<i>Lewis Kaufman and Michael J. Ross</i>	
Introduction	381
Novel Biomarkers	382
Host Genetic Determinants of Susceptibility to HIV Infection	382
Chemokines/Chemokine Receptors	382
CCR5 Variants	384
CCR2-64I Variant	385
SDF1-3'A Variant	385
Other Chemokine Polymorphisms	385
Human Leukocyte Antigens	386
HLA Heterozygosity Protects Against Progression to AIDS	386
Protective HLA Alleles	386
HLA Alleles Associated with Rapid Progression to AIDS	387
Other Host Genetic Factors Associated with HIV-Related Outcomes	387
Host Factors Associated with Non-Opportunistic HIV-Related Diseases	387
HIV-Associated Nephropathy	387
HIV-Associated Dementia	388
Clinical Markers	389
CD4+ T-Cell Depletion	389
Plasma Viral Load	389
Combination of Viral Load, CD4+ Count, and Proviral DNA Levels	390
Generalized Immune Activation	390
Conclusion	391
Summary Points	393
References	393

16 Biomarkers of In Vitro Drug-Induced Mitochondrial Dysfunction	401
<i>James A. Dykens and Yvonne Will</i>	
Introduction	401
Magnitude of the Problem	402
Mitochondrial Physiology	403
Drug-Induced Mitochondrial Dysfunction (DIMD) Has Been Overlooked	406
Novel Methods to Detect Mitochondrial Dysfunction In Vitro	407
An Emerging Model of Idiosyncratic Drug Toxicity	409
Mitochondrial Diseases	411
Potential Biomarkers of Mitochondrial Dysfunction	413
Animal Models	416
Summary Points	417
References	417
 SECTION III: TECHNOLOGY FOR BIOMARKER DETECTION	 423
17 Immunoassay-Based Technologies for the Measurement of Biological Materials Used for Biomarkers Discovery and Translational Research	425
<i>Vincent Ricchiuti</i>	
Introduction	425
Immunoassay and Immunochemistry	426
Background	426
Basic Principles	426
Radioimmunoassays	427
Overview	427
Principle of Radioimmunoassay	428
Enzyme-Linked Immunosorbent Assay and Enzyme Immunoassay	431
Overview	431
Principle of Enzyme Immunoassay	432
Fluorescent and Chemiluminescent Immunoassays	433
Fluorescent Immunoassays	433
Heterogeneous Fluorescent Immunoassays	433
Homogenous Fluorescent Immunoassays	433
Fluorescence Polarization Immunoassay (FPIA)	434
Chemiluminescent Immunoassays	435
Multiplexing Using Antibody Array and Bead Immunoassays	436
Planar Protein Array Formats	437
Suspension or Bead-Based Arrays	440
Example of Multiplexing Technology	440
Simultaneous Multi-Analyte Detection	441
Introduction	441
Multiple Bead Particle Technology	441

Applications	443
The Future	445
Electrochemiluminescence (ECL) Microarrays	445
ECL Diagram	446
Detection	446
Multi Arrays Technologies	447
Biochip Array Technology	447
Biochip Manufacturing	448
Applications	448
Future of Immunoassays	448
Summary Points	449
Acknowledgments	450
References	450
18 Nanoscale Techniques for Biomarker Quantification	457
<i>Madhukar Varshney and Harold G. Craighead</i>	
Introduction	457
Nanoscale Sensing Techniques for Biomarker Quantification	458
Optical Detection	459
Bio-Barcode Assay-Based Sensors	459
Quantum Dots-Based Sensors	461
Dye-Doped Nanoparticles-Based Sensors	464
Surface Enhanced Raman Spectroscopy-Based Sensors	465
Dynamic Light Scattering	468
Mechanical Detection	470
Nanomechanical Cantilever-Based Sensors	470
Electrical Detection	473
Field Effect Transistor-Based Sensors	473
Liposomes-Based Sensors	475
Magnetic Detection	478
Giant Magnetoresistance-Based Sensors	478
Future Trends	482
Conclusion	483
Summary Points	484
References	485
19 Immunodiagnosics with a Focus on Lateral Flow Point-of-Care Devices	495
<i>Roy R. Mondesire, Glen M. Ford, Hannie F. Ford, and Stephen C. Mefferd</i>	
Introduction	495
Antibodies in Immunoassays	496
Structure and Function of Antibodies	497
Kinetics of Antibody-Antigen Reactions	499

Polyclonal Antibodies	500
Hybridoma Technology	500
Rapid Manual and Rapid Automated Immunoassays	501
Elements of Immunoassays: Soluble Labels and Detection	502
Homogeneous Enzyme Immunoassays	503
Signal Measurement Methods	504
Colorimetry	504
Fluorometry	504
Time-Resolved Fluorescence	505
Luminescence	505
Principles of Binding	505
Non-Specific Interactions in Immunoassays	506
Colloidal and Particle Immunoassays	506
Flow-Through Assays	506
Particle Capture	506
Fluorochrome-Dyed Microspheres	506
Point-of-Care Lateral-Flow Assay Technology	507
Introduction to Traditional Lateral Flow Tests	507
Nucleic Acid Detection and Lateral Flow	510
Principle of the Lateral-Flow Procedure for Nucleic Acid Detection	511
Haptenized Primers	511
Haptenized Detection Probes	512
Molecular Detection of Chlamydia Trachomatis—A Major Agent of Sexually Transmitted Infections	512
Pathogenic Bacteria Detection with Bacteriophage	512
Sensitivity of Lateral-Flow Technology	513
Summary Points	513
Useful Information for Future Trends	513
Emerging Technologies	513
References	514

SECTION IV: HOT TOPICS IN BIOMARKER RESEARCH **517**

20 Biomarkers for Environmental Exposure **519**

Jane E. Gallagher, Elaine A. Cohen Hubal, and Stephen W. Edwards

Introduction	519
Need for Biomarkers to Support Environmental Risk Assessment	520
Considerations for the Use of Biomarkers in Environmental Risk Assessment	522
Applications	524
Biomonitoring Studies	524
Interpretation of Biomonitoring Data	527

Cumulative Risk Assessment	532
Molecular Epidemiology	534
Emerging Issues	537
Toxicity Pathway-Based Risk Assessment	537
Systems Biology to Support Risk Assessment	539
Summary Points	540
Acknowledgments	541
References	541
21 Clinical Study Design in Biomarker Research	549
<i>Orfeas Liangos and Bertrand L. Jaber</i>	
Overview of Clinical Study Design	549
Case Study	549
Case Series	549
Cross-Sectional Study	549
Case Control Study/Nested Case Control Study	550
Cohort Study	550
Experimental Studies	551
Uncontrolled Trial	551
Controlled Trial	552
Blinded/Un-blinded Design	553
Parallel Two-Arm/Multiple-Arm and Crossover Design	553
Biomarkers in Observational Studies	553
Biomarkers for Disease Detection and Diagnosis	554
Biomarkers for Disease Monitoring	556
Biomarkers for Disease Prognostication	556
Biomarkers in Interventional Studies	557
Biomarkers for Treatment Response	557
Biomarkers for Monitoring Toxicity	558
Conclusion	558
Summary Points	558
References	558
22 Statistical Issues in Biomarker Research	561
<i>Daniel Holder and Matthew Schipper</i>	
The Role of Statistics in Biomarker Discovery, Development, and Qualification	561
Types of Biomarkers	562
Stages of Development	563
Kidney Project Background	564
Statistical Methods/Metrics for Assessing Biomarker Performance	566
Sensitivity, Specificity, and Receiver-Operator Characteristic Curves	566

Assessing Whether a Marker Adds Value to Other Markers	569
Errors in the Reference Standard	572
Planning Human Clinical Trials	575
Prognostic Biomarkers and Other Topics	577
Biases in Biomarker Studies	578
Discussion	578
Summary Points	579
Acknowledgments	580
References	580
23 Regulatory Perspective for Biomarker Qualification from the U.S. FDA	581
<i>Federico Goodsaid</i>	
Overview	581
Regulatory Paths in Biomarker Evaluation and Qualification	583
Evidentiary Recommendations	586
Harmonization	586
Summary Points	587
References	587
24 The European Medicines Agency Approach	589
<i>Marisa Papaluca Amati and Spiros Vamvakas</i>	
Introduction	589
European Medicines Agency and Biomarkers: Briefing Meetings and Scientific Advice	590
New Procedure for the Qualification of Novel Methodologies	592
Current Status	594
Index	595